This week's roundup of Houston innovators includes Loretta Williams Gurnell of the SUPERGirls SHINE Foundation, Al Ansari of FreshBrew, and Carolyn Rodz of Hello Alice. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from advocacy to coffee manufacturing — recently making headlines in Houston innovation.

Loretta Williams Gurnell, founder and executive director of the SUPERGirls SHINE Foundation

Loretta Williams Gurnell, founder and executive director of the SUPERGirls SHINE Foundation, joins the Houston Innovators Podcast to discuss how she's impacting young women in STEM. Photo courtesy of SUPERGirls SHINE Foundation

Years ago, through her own experience working with students, Loretta Williams Gurnell realized there wasn't any initiative connecting the dots for young women in terms of translating their state-mandated math and science classes into successful careers and job opportunities.

She set out to connect those dots and increase STEM opportunities for young women and launched her organization SUPERGirls SHINE Foundation in early 2016 to focus on programming to spark STEM interest and education for girls age 10 to 17. Later, amid the pandemic, she realized she needed to do more than just put on events and programming for these young women.

"We had to look at what's going to be longterm for these girls. How can we take the programatic piece that we do so well and make it a part of their lifestyle and decision making opportunities, so we had to pivot," she says on the Houston Innovators Podcast. Click here to read more.

Al Ansari, president and CEO of FreshBrew

FreshBrew has upgraded to some high-tech roasting equipment. Image courtesy of FreshBrew

Al Ansari takes coffee seriously — and he's putting his money where his mouth is. Houston-based FreshBrew, one of the largest private-label coffee and tea producers in the country, announced this month the recent investment of $10 million into its specialty roasting and production divisions.

The company, which supplies specialty blended coffee, tea and total beverage solutions to hospitality and retail business, is expanding its current roasting production and will fund extraction, bottling and canning capabilities, making FreshBrew one of only a few companies in the country to offer total end-to-end beverage solutions. The expansion, which is on the same land the company has owned since its inception in 1995, is slated to be complete in early 2023.

“Over the years, we take a myopic approach with our customers, we look at what they want to achieve and look at their market, and blend their wants and our knowledge and create custom profiles for them,” says Ansari, president and CEO of FreshBrew. Click here to read more.

Carolyn Rodz, founder and CEO of Hello Alice

In an interview with InnovationMap, Carolyn Rodz, CEO and founder of Hello Alice, explains how the partnership came about and how the program will significantly move the needle on equitable access to capital for small business owners. Photo courtesy of Hello Alice

Last month, Hello Alice — now with 1 million members in its community — announced a new program with MasterCard that provides small business owners a simpler way to unlock access to capital.

The Hello Alice Small Business Mastercard offers users expert business advice, business insights, cash back, and a rewards program that gives entrepreneurs points for completing business-advancing activities on the Hello Alice platform.

"As a small business owner myself, I've created a card that I wish I would have had," Carolyn Rodz, CEO and founder of Hello Alice, tells InnovationMap. "We really looked at where are the gaps for these business owners and the things they don't already have or are unable to access." Click here to read more.

FreshBrew has upgraded to some high-tech roasting equipment. Image courtesy of FreshBrew

Houston-based coffee company invests $10M into expansion, new state-of-the-art roasters

boom, roasted

Houston-based FreshBrew, one of the largest private-label coffee and tea producers in the country, announced this month the recent investment of $10 million into its specialty roasting and production divisions.

FreshBrew supplies specialty blended coffee, tea and total beverage solutions to companies in the food service, convenience store, hospitality and retail sectors.

The investment will expand current roasting production and will fund extraction, bottling and canning capabilities, making FreshBrew one of only a few companies in the country to offer total end-to-end beverage solutions. The expansion, which is on the same land the company has owned since its inception in 1995, is slated to be complete in early 2023.

“Over the years, we take a myopic approach with our customers, we look at what they want to achieve and look at their market, and blend their wants and our knowledge and create custom profiles for them,” says Al Ansari, president and CEO of FreshBrew.

As part of the investment, FreshBrew upgraded its existing roasters and purchased two additional roasters and added 11 packing lines for a total of 25 to accommodate increased demand. In addition, the company expanded its team lines and added sugar to its production to allow for sweet tea products.

Construction is now underway to transform the 40,000-square-feet of vending space to allow for extraction, bottling and canning production in-house. The company also acquired an additional 25,000 square-feet of space, creating a combined total of 140,000 square feet for the roasting plant and warehouse. The company plans to add up to 50 employees with the expansion and is currently at 100.

“I think COVID really changed the game for everybody in doing business, especially in the coffee market – people want innovative products, flavored coffee, cold coffee now. We believe unique items will be the wave of the future – the companies that are the most nimble will succeed and I think that’s what we do very well,” says Ansari.

Earlier this year, FreshBrew sold the vending division of the company to Compass Group North America, the owner of Canteen Vending Services, in response to rapidly increasing customer demand for production services.

Al Ansari is the president and CEO of FreshBrew. Photo courtesy of FreshBrew

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.